Exploring how vision problems in kidney disease patients may lead to cognitive decline and dementia.
Official title: Understanding Vision Impairment in ESKD to Prevent Cognitive Impairment and Dementia/Alzheimer’s disease: the VIS-HD Cohort Study
Funded at New York University School of Medicine · NIH-11047340 · Data updated 2026-11-12
This study is looking at how vision problems might affect thinking skills in people with severe kidney disease, and it hopes to find ways to improve both vision and overall health for these patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $829,211 |
| NIH project number | 1R01AG086252-01A1 |
| Project ID | NIH-11047340 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with end-stage kidney disease and experiencing vision impairment.
✕Less likely to help
Patients without end-stage kidney disease or those who do not have vision impairment may not benefit from this research.
What this research studies
This research investigates the link between vision impairment and cognitive decline in patients with end-stage kidney disease (ESKD). It aims to identify the prevalence and causes of vision issues in this population, as well as the potential for reversing these impairments. The study will also explore the cognitive effects of vision loss and the barriers to effective vision screening and treatment. By understanding these factors, the research seeks to improve the overall health and quality of life for ESKD patients.
Why it matters
Potential benefit: If successful, this research could lead to improved screening and treatment strategies that may reduce the risk of cognitive decline and dementia in patients with ESKD.
How similar studies have gone: Previous research has indicated a strong association between vision impairment and cognitive decline in older adults, suggesting that this approach has potential for success.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Mcadams Demarco, Mara a. — New York University School of Medicine
- Study coordinator: Mcadams Demarco, Mara a.
Related research
Other NIH-funded projects on the same topics.
-
Global picture of dementia risk and memory loss across the world
A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.
-
PNA5 for VCID and Alzheimer's Dementias: A first-in-human safety study
A first-in-human trial tests a new drug, PNA5, to see if it is safe and tolerable for adults with vascular cognitive impairment and Alzheimer's-related dementias.
-
Global picture of dementia and Alzheimer’s risk across populations
A large international effort gathers health data from many cohorts to understand what increases or lowers the risk of dementia and Alzheimer's disease around the world.
-
Global patterns of cognitive impairment and Alzheimer's dementia
Bringing together memory-study data from around the world to find lifestyle and environmental factors people can change to lower the risk of Alzheimer's and related dementias.
-
A brain-boosting peptide to help people at risk of vascular dementia and Alzheimer’s disease
A new drug-like peptide (PNA5) is being studied to reduce brain inflammation and improve blood flow in people at risk for vascular dementia and Alzheimer's-related dementia.
-
Scale-up of a peptide therapy to help brain blood flow and inflammation in people at risk for Alzheimer’s-related dementias
A small US-based project will scale up manufacturing of a new peptide medicine (PNA5) intended to help people at risk for Alzheimer’s-related dementia and vascular dementia by improving brain blood flow and reducing inflammation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.